David Lamond, Director at Quince Therapeutics, Inc. (QNCX), bought 57,369 shares at $1.02 ($58K) on 2023-12-06, disclosed to the SEC on 2023-12-07.
Open-market purchase of $58k QNCX by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.01 | 19,123 | $19K | 33.2% |
| 2 | $1.02 | 19,123 | $20K | 33.6% |
| 3 | $1.01 | 19,123 | $19K | 33.2% |
| Total | $1.01 avg | 57,369 | $58K | 100% |
| Filing → |
| QNCX | BUY | 2023-08-31 | $216K | — | Filing → |
| QNCX | BUY | 2023-08-17 | $620K | — | Filing → |
| AMTI | BUY | 2022-05-23 | $211K | — | Filing → |